Intimation to stock Exchanges

Quick Explore

Intimation to Stock Exchange for 2026-2027
icon-pdf
Pre-Intimation of Board Meeting
28th Sep 2026
icon-pdf
Allotment of 12,168 equity shares under ESOS 2013-A Scheme and the Cipla ESAR Scheme 2021 of the Company
24th Sep 2026
icon-pdf
Change in Senior Management Personnel
22nd Sep 2026
icon-pdf
ESG Rating assigned by Niche Ninety Nine Capability and Certifications
18th Sep 2026
icon-pdf
Press Release - Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
03rd Sep 2026
icon-pdf
Newpaper Advertisement regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares
02nd Sep 2026
icon-pdf
Press Release - Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)
31st Aug 2026
icon-pdf
Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
28th Aug 2026
icon-pdf
Restructuring: Transfer of Ownership of Aspergen Inc., USA to Aspergen Limited, India
27th Aug 2026
icon-pdf
Schedule of Analysts/ Institutional Investor Meetings
27th Aug 2026
 
BSE and NSE Quotes by TradingView

The displayed data is not in real time and may have streaming delays.